Chiesi has focused on researching treatments for patients with diseases that require special care. These efforts and investment led to the development of pulmonary surfactants and other innovations, the reasons why the company has become the world leader in neonatology.
Chiesi has been supporting research in the neonatology community for more than 20 years. The company's continued efforts in the neonatology area are now focused on combining the use of pulmonary surfactants with new ventilation strategies, the use of caffeine citrate for apnoea in premature babies, the development of a synthetic surfactant and a product for bronchopulmonary dysplasia.
The information contained in this section is directed to the health professional (resident in Spain) empowered to prescribe medicinal products, so a specialized training for proper interpretation is required. The products may have an authorized data sheet different in other countries. If you check the "OK" button, you are expressing the will of access to information specifically aimed at health professionals.